Sichuan Kelun-Biotech Seeks HK$2.7 Billion via Share Placement
MT Newswires Live
Jul 08
Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) is looking to raise estimated net proceeds of about HK$2.72 billion through a share placement, according to a Hong Kong bourse filing Wednesday.
The drugmaker is placing 5.84 million new H-shares at HK$470.20 each.
The net proceeds will be used for research and development, clinical trials, registration filings, manufacturing and commercialization of its products, expansion of its research and development capabilities and product pipeline, and working capital and general corporate purposes.
The shares represent about 2.50% of the company's existing issued share capital and about 2.44% of its enlarged share capital after the placement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.